| TALAZOPARIB TOSYLATE | None | ||
| 0.25MG, 1MG, 0.5MG, 0.75MG, 0.1MG, 0.35MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA | |||
|
Yes
| |||
| TALZENNA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
|---|---|---|---|---|---|---|
| *** ********* | ||||||
| ************************** ********** ** ****(***-******)********** (****) | ************************** ********** ** ****(***-******)********** (****) | *********** (**,**)-*-******-*-(*-************)-*-(*-******-**-*,*,*-*******-*-**)-*,*-*******-**-******[*,*,*-**]**********-*(**)-*** ******** **** | ************************** ********** ** ****(***-******)********** (****) | *********** (**,**)-*-******-*-(*-************)-*-(*-******-**-*,*,*-*******-*-**)-*,*-*******-**-******[*,*,*-**]**********-*(**)-*** ******** **** | ************************** ********** ** ****(***-******)********** (****) |
| TALAZOPARIB TOSYLATE | None | ||
| 0.1MG, 0.25MG, 0.35MG, 0.5MG, 0.75MG, 1MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). | |||
|
Yes
| |||
| TALZENNA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
|---|---|---|---|---|---|---|
| *** ********* | ||||||
| ************************** ********** ** ****(***-******)********** (****) | ************************** ********** ** ****(***-******)********** (****) | *********** (**,**)-*-******-*-(*-************)-*-(*-******-**-*,*,*-*******-*-**)-*,*-*******-**-******[*,*,*-**]**********-*(**)-*** ******** **** | ************************** ********** ** ****(***-******)********** (****) | *********** (**,**)-*-******-*-(*-************)-*-(*-******-**-*,*,*-*******-*-**)-*,*-*******-**-******[*,*,*-**]**********-*(**)-*** ******** **** | ************************** ********** ** ****(***-******)********** (****) |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|